PURPOSE: Myocardial viability was evaluated by magnetic resonance imaging (MRI) in patients with chronic total coronary occlusion (CTO) treated with a drug-eluting stent. Change in left ventricular ejection fraction (LVEF) was analysed. MATERIALS AND METHODS: Twenty-three patients with CTO underwent delayed-enhancement (DE) and low-dose dobutamine MRI (LD). Diastolic wall thickness (DWT), dobutamine-induced systolic wall thickening (SWT) and DE transmural extension were quantitatively assessed in vessel-related segments, calculating the contribution of viable tissue to SWT, expressed as viability index (VI)=[SWTx(100 - DE)]/100. Patients with transmural enhancement were excluded from revascularisation. At 6 months follow-up, patients underwent coronary angiography (CA) and MRI. Functional recovery was defined as a 2-mm increase in SWT. RESULTS: Transmural enhancement (mean DE 62.88+/-37.18] was present in three patients. Mean DWT, SWT, VI and DE of recanalised patients were 8.03+/-2.35, 2.64+/-1.56, 1.77+/-1.48 mm and 41.97+/-30.32. Revascularisation was successful in 14/16. Follow-up CA showed patency of treated vessels. Functional recovery was achieved in 13 patients. Functional recovery showed significant correlation with SWT (beta 1,779, p=0.015), and even higher correlation with VI (beta 2.032, p=0.011). LVEF improved significantly [Delta 95% confidence interval (CI) -4.47, p=0.0203). CONCLUSIONS: Invasive CTO treatment has beneficial effects on myocardial contractility that can be predicted by VI, and on LVEF.
PURPOSE: Myocardial viability was evaluated by magnetic resonance imaging (MRI) in patients with chronic total coronary occlusion (CTO) treated with a drug-eluting stent. Change in left ventricular ejection fraction (LVEF) was analysed. MATERIALS AND METHODS: Twenty-three patients with CTO underwent delayed-enhancement (DE) and low-dose dobutamine MRI (LD). Diastolic wall thickness (DWT), dobutamine-induced systolic wall thickening (SWT) and DE transmural extension were quantitatively assessed in vessel-related segments, calculating the contribution of viable tissue to SWT, expressed as viability index (VI)=[SWTx(100 - DE)]/100. Patients with transmural enhancement were excluded from revascularisation. At 6 months follow-up, patients underwent coronary angiography (CA) and MRI. Functional recovery was defined as a 2-mm increase in SWT. RESULTS: Transmural enhancement (mean DE 62.88+/-37.18] was present in three patients. Mean DWT, SWT, VI and DE of recanalised patients were 8.03+/-2.35, 2.64+/-1.56, 1.77+/-1.48 mm and 41.97+/-30.32. Revascularisation was successful in 14/16. Follow-up CA showed patency of treated vessels. Functional recovery was achieved in 13 patients. Functional recovery showed significant correlation with SWT (beta 1,779, p=0.015), and even higher correlation with VI (beta 2.032, p=0.011). LVEF improved significantly [Delta 95% confidence interval (CI) -4.47, p=0.0203). CONCLUSIONS: Invasive CTO treatment has beneficial effects on myocardial contractility that can be predicted by VI, and on LVEF.
Authors: Christoph Klein; Stephan G Nekolla; Frank M Bengel; Mitsuru Momose; Andrea Sammer; Felix Haas; Bernhard Schnackenburg; Wolfram Delius; Harald Mudra; Dieter Wolfram; Markus Schwaiger Journal: Circulation Date: 2002-01-15 Impact factor: 29.690
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: V Dzavik; R G Carere; G B Mancini; E A Cohen; D Catellier; T E Anderson; G Barbeau; C Lazzam; L M Title; P B Berger; M Labinaz; K K Teo; C E Buller Journal: Am Heart J Date: 2001-08 Impact factor: 4.749
Authors: Gerald S Werner; Andreas Krack; Gero Schwarz; Dirk Prochnau; Stefan Betge; Hans R Figulla Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Theodorus A M Kaandorp; Jeroen J Bax; Joanne D Schuijf; Eric P Viergever; Ernst E van Der Wall; Albert de Roos; Hildo J Lamb Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: Timo Baks; Robert-Jan van Geuns; Dirk J Duncker; Filippo Cademartiri; Nico R Mollet; Gabriel P Krestin; Patrick W Serruys; Pim J de Feyter Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Angela Hoye; Kengo Tanabe; Pedro A Lemos; Jiro Aoki; Francesco Saia; Chourmouzios Arampatzis; Muzaffer Degertekin; Sjoerd H Hofma; Georgios Sianos; Eugene McFadden; Willem J van der Giessen; Pieter C Smits; Pim J de Feyter; Ron T van Domburg; Patrick W Serruys Journal: J Am Coll Cardiol Date: 2004-06-02 Impact factor: 24.094
Authors: Loes P Hoebers; Bimmer E Claessen; George D Dangas; Truls Råmunddal; Roxana Mehran; José P S Henriques Journal: Nat Rev Cardiol Date: 2014-05-27 Impact factor: 32.419
Authors: Eleonora Melotti; Marta Belmonte; Carlo Gigante; Vincenzo Mallia; Saima Mushtaq; Edoardo Conte; Danilo Neglia; Gianluca Pontone; Carlos Collet; Jeroen Sonck; Luca Grancini; Antonio L Bartorelli; Daniele Andreini Journal: Front Cardiovasc Med Date: 2022-05-02
Authors: Henk Everaars; Stefan P Schumacher; Wijnand J Stuijfzand; Martijn van Basten Batenburg; Jennifer Huynh; Pepijn A van Diemen; Michiel J Bom; Ruben W de Winter; Peter M van de Ven; Ramon B van Loon; Albert C van Rossum; Maksymilian P Opolski; Alexander Nap; Paul Knaapen Journal: Int J Cardiovasc Imaging Date: 2021-08-02 Impact factor: 2.357